Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

NRXP - NRx Pharmaceuticals, Inc. So'nggi... | Finranks

Home

NRXP

N

NRx Pharmaceuticals, Inc. (NRXP)

NCM – Real vaqt narxi. Valyuta: USD

2.19

-0.19 (-7.98%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

2.13

-0.06 (-2.74%)

Bozordan keyin: Mar 27, 2026, 7:33 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

NRx Pharmaceuticals, Inc. (NRXP) Q4 2025 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NRXP) Q4 2025 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NRXP) Q4 2025 Earnings Call Transcript

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress

Key highlights for the first full year of operation under the new management team include: A year-over-year reduction in operating expenses with $7.8 Million cash on hand at year end. With ongoing revenue from operations and current ATM trends, the Company anticipates adequate resources to support operations through 2026, with anticipation of continued revenue growth.

NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates

NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates

NRx Pharmaceuticals, Inc. (NRXP) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to a loss of $0.3 per share a year ago.

NRx Pharmaceuticals, Inc. (NRXP) Shareholder/Analyst Call Prepared Remarks Transcript

NRx Pharmaceuticals, Inc. (NRXP) Shareholder/Analyst Call Prepared Remarks Transcript

NRx Pharmaceuticals, Inc. (NRXP) Shareholder/Analyst Call Prepared Remarks Transcript

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026.

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx's Preservative-Free Ketamine Application

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx's Preservative-Free Ketamine Application

Determination of bioequivalence to the Reference Listed Drug is essential for approval of an Abbreviated New Drug Application (ANDA). FDA has advised NRx in written correspondence that it has not identified any bioequivalence deficiencies in the Company's Preservative-Free Ketamine product.

NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

NRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and FDA Center for Drug Evaluation and Research. Minutes are consistent with previously announced oral guidance outlining a path to New Drug Approval of NRX-100 for a broadened indication of treating depression, including patients with suicidality.

Videolar

No Data

There is no data to display

Press-relizlar

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress

Key highlights for the first full year of operation under the new management team include: A year-over-year reduction in operating expenses with $7.8 Million cash on hand at year end. With ongoing revenue from operations and current ATM trends, the Company anticipates adequate resources to support operations through 2026, with anticipation of continued revenue growth.

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx's Preservative-Free Ketamine Application

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx's Preservative-Free Ketamine Application

Determination of bioequivalence to the Reference Listed Drug is essential for approval of an Abbreviated New Drug Application (ANDA). FDA has advised NRx in written correspondence that it has not identified any bioequivalence deficiencies in the Company's Preservative-Free Ketamine product.

NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

NRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and FDA Center for Drug Evaluation and Research. Minutes are consistent with previously announced oral guidance outlining a path to New Drug Approval of NRX-100 for a broadened indication of treating depression, including patients with suicidality.

HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD

HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD

Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications. Clinical leadership by physicians trained at Harvard, Johns Hopkins, Georgetown, and other leading Universities.